Merck has announced that its animal health division, formerly known as Intervet/Schering-Plough, has changed its name to MSD Animal Health in countries outside the United States and Canada from today.
Intervet/Schering Plough will now be known as Merck Animal Health in the United States and Canada.
Raul Kohan, President of Merck Animal Health said: "The name change reflects Merck's commitment to animal health and its complementary role to the overall business. We are unwavering in our commitment to veterinarians, producers, pet owners and society as a whole. We aim to generate additional value and sustained growth by continuing to provide integrated solutions with innovative animal health products and services to meet the evolving needs of our customers."
Mr. Kohan continued: "With the scientific and business backing of Merck, Merck Animal Health possesses the necessary mix of resources to enhance our position as an industry leader."
Merck says it values the diversification that Merck Animal Health brings to its portfolio, and sees growth opportunities in the business that can be leveraged across both animal and human health. The company intends to capitalize on Merck Animal Health's broad and innovative portfolio going forward, and to develop the unit into a best-in-class global animal health leader.
The name change follows the joint announcement on March 22, 2011 by Merck and sanofi-aventis that ended plans to form a new animal health joint venture. Both companies mutually decided to discontinue their agreement primarily because of the increasing complexity of implementing the proposed transaction.
Vetoquinol UK Ltd is launching a dedicated large animal/equine sales force on the 1st July.
The company says the move reflects the change in cattle and equine veterinary practice to become specialists.
Vetoquinol's large animal brands include: Marbocyl®, Sedalin®, Equistro®, Tolfine®, Pro Rumen and Locatim®.
The new team comprises:
The new sales team will be managed jointly by Hugh Gibson and Stuart Wade.
For further information or to make an appointment please contact your local Territory Manager direct or telephone 01280 825424
Dechra Veterinary Products has added to its Veterinary Essentials range of veterinary-licensed post-patent products with the launch of Fiprocat and Fiprodog, a fipronil spot-on solution for the treatment and prevention of on-animal flea infestations in cats and dogs.
Available in packs of 3 or 6 pipettes, Fiprocat and Fiprodog are only distributed through the veterinary channel. Dechra highlights the product's convenient self-standing pipette. which it says makes the process of applying the spot-on easier.
Dechra says it offers a wealth of client support material, and practice promotional support to go with the product.
Fiprocat and Fiprodog can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).
Rob Simpson at Dechra said: "Fipronil has been used in the treatment and prevention of on-animal flea infestations for many years and is one of the most commonly used treatments in practice. Fiprocat and Fiprodog join R.I.P Fleas Extra to offer a cost effective complete flea solution to tackle both on-animal and environmental flea infestations."
Petplan has launched a new look policy range to give pet owners more comprehensive cover and make it easier for them to understand the types of cover available.
Simon Masding, Petplan's Head of Sales and Partnerships said the refreshed policies will not only benefit the pet and their owner but the changes will also allow veterinary staff to explain the policies with a lot more clarity: "Since Petplan started 35 years ago the pet insurance market and vet industry has changed significantly, especially in the last few years. There are now over 250 policies in the market with varying benefits and levels of cover, which often confuses customers to a point where they think they're getting lifetime cover but they're instead trapped with a restrictive policy.
"The veterinary industry is also continually changing with advances in new technology and better diagnostics allowing the industry to save and treat more pets, which means our policies need to evolve with them."
To better understand these changing market dynamics, Petplan held focus groups with veterinary staff from across the UK and undertook extensive research with charities, breeders, customers and non-customers.
Apparently, the feedback showed that Petplan needed to communicate its range of policies more clearly, to shift away from the confusion created by other brands and meet the changing demands of the vet industry and pet owners better.
For this reason, Petplan says it has simplified its policy range, adding and increasing each policy's benefits, making a 12 month policy available for practices to offer, and developing easy-to-understand policy names.
Petplan's new look policies for both cats and dogs are:
Petplan says its Covered for Life policies, Petplan Ultimate and Petplan Classic, will continue to provide pet owners with the best cover in the market. However, the company recognises that these policies are not always suitable for people with older pets or a limited budget.
Simon said: "Petplan Essential, our 12 month policy, will also now be available for veterinary staff to offer to their customers. While our Covered for Life Ultimate and Classic will continue to be our leading policies and at the heart of what we do, it's better that a pet owner has some type of cover rather than nothing at all and Essential is a market leading 12 month policy."
Zeta Frasca, practice owner and vet at Kitten to Cat in Richmond London said: "These changes will not only make it clearer for the pet owner but it will also make it a lot easier for us as an industry to explain pet insurance to our clients, which is really important."
For more information about Petplan's new look policies visit www.petplan.co.uk, call their dedicated Vetline on 0800 3168 8900 or talk to your Petplan Business Developer.
The following table outlines each policy and its benefits:
BCF Technology has launched a competition in which the person who submits the best photograph with the theme of: All in a day's work - animal imaging, will win an iPad 2.
To enter the competition, you need to post your photographs, (and tell BCF a little about the story behind the images) at www.facebook.com/bcftechnology or email them to: info@bcftechnology.com
Jason Rogers, Marketing Manager at BCF said: "We wanted to create a fun way to show just how interesting and different each days work is when imaging animals. We have made the competition open to all that work with animal imaging including our staff, dealers and vets, vet nurses, animal contractors, etc from all over the world.
"It is great to see the BCF office in the States and our international dealers also promoting the competition in their own countries, making the competition truly international. Response to the competition has been fantastic - see our facebook page to some entries for yourself."
The closing date for the competition is 30th September 2011.
For more information, visit: www.bcftechnology.com
The Land Rover Burghley Horse Trials has announced a £15,000 bursary to the Animal Health Trust. The bursary will be used to help fund the development of a rapid result blood test to identify horses infected with Strangles.
The AHT has already developed a test that can detect the disease, however the result is not known for 48 hours. The aim of the new research is to develop the test to produce a result within 10 minutes. The test, which is being developed in conjunction with Forsite Diagnostics Ltd, will be a useful tool for disease screening at sales and competitions.
"As an independent charity we receive no government funding and this bursary is extremely important to us and we are delighted to be working in partnership with The Land Rover Burghley Horse Trials on this specific project," said Dr Richard Newton of the AHT who is carrying out the research in partnership with Professor Andrew Waller. "Without this vital funding to carry out the painstaking work that will give us the confidence to launch the test, it will remain no more than a theoretical possibility."
The Bursary will be presented at this year's Land Rover Burghley Horse Trials (1- 4 September 2011) - in recognition of the 50th Anniversary of the event.
"With increasing horse movement, not only world-wide but closer to home between competitions and livery yards, preventing the spread of disease is an increasingly important challenge facing the horse world," said Elizabeth Inman Director of the Trials. "We are delighted to be able to play a part in this challenge and hope that this anniversary bursary will help to fast-track this new test out of the laboratory and into the field and thereby help reduce the spread of what is a horrible disease for horses and owners."
Boehringer Ingelheim Vetmedica has launched new, more palatable Metacam Chewable Tablets.
According to the company, the tablets are proven to be taken by 90% of dogs voluntarily1 and 80% will even take them from the floor1 which aids compliance. Available in pop-through blister strips of seven for easy dispensing and administration, the 1mg and 2.5mg Metacam Chewable Tablets are packed in boxes of 84 and priced the same per tablet as the current tablet range.
Claire Fowler, companion animal marketing manager at Boehringer Ingelheim, said: "The existing Metacam Chewable Tablets are readily accepted by most dogs. However, to appeal to as many dogs as possible, we have launched an even more appetising 'beefed up' meaty flavour."
For further information on the new flavoured Metacam tablets, including special offers, please contact your Boehringer Ingelheim territory manager or call 01344 746959.
The BSAVA has announced the launch of its third smartphone app - the BSAVA Small Animal Formulary App.
This member-only access app is available to download now from iTunes and Android Market and offers the same reference materials found in the latest 7th edition printed version.
The BSAVA says the app contains more than 450 drug monographs and a wealth of additional information, allowing easy and rapid access to vital information about those medications that veterinary surgeons most commonly prescribe. It is hoped that the convenience of having the BSAVA Small Animal Formulary on a smartphone will mean that vets in practice will always have this valuable reference tool within easy reach.
Once the app is installed it will ask for a validation code that can be obtained from the smartphone app validation code page within My BSAVA pages at www.bsava.com. All future BSAVA member-only smartphone apps will be validated using the same process.
BSAVA IT Manager Emma Hayes said: "BSAVA is continually aiming to provide a range of valuable member benefits in a variety of formats so they can be used in the most efficient and effective way by our members. The BSAVA Formulary was a natural candidate for release as a mobile application, following the successful launch as an online searchable database at Congress in April. By developing this application it has also provided us with a platform that will enable us to produce additional useful applications in the future that can provide unrestricted content for our members."
The BSAVA Small Animal Formulary App follows on from the BSAVA Congress App and the BSAVA Guide to the use of Veterinary Medicines App. You can find out more about these other BSAVA smartphone apps through My BSAVA at www.bsava.com.
Ceva Animal Health has added a new session to its Cardio Academy CPD website entitled 'Thoracic X-rays: Normal Features'.
In this 30 minute multimedia presentation, the cardiology specialist Nicole Van Israël discusses how the normal thoracic radiograph should appear, as well as the differences observed between breeds. Participants can then receive a CPD certificate by completing the quiz for this session. The Cardio Academy CPD website is free of charge and can be accessed by visiting http://www.cardioacademy.cevalearn.com/.
The first three sessions in the series can still be viewed on the website. They cover the 'Pathophysiology of Mitral Valve Disease, by Adrian Boswood, 'Clinical Examination of the Cardiac Dog', by Gérard Le Bobinnec and 'Thoracic X-rays: How to Proceed' by Nicole Van Israël.
Dechra Veterinary Products has added a new webinar: 'Otitis Externa - Recent advances in the treatment of ears' to The Dechra Academy, the online training suite from Dechra Veterinary Products.
Presented by Sue Paterson, MA VetMB DVD DipECVD MRCVS RCVS & European Specialist in Veterinary Dermatology, the webinar accounts for 1.5 hours CPD and covers such topics as ear anatomy, cytology and the creation of treatment plans.
Carol Morgan, Dechra Brand Manager said: "We are dedicated to providing educational resources to support the veterinary profession. The otitis webinar is the latest addition to our range of high quality key-opinion-leader-led CPD on The Dechra Academy."
The webinar is now available to view on demand at www.dechra.co.uk/academy.
Virbac Animal Health has developed a 'Yield Wheel' to show vets the additional income that farmers can achieve through taking a tailored and more flexible approach to the management of their dairy herd through the dry period.
The company says this approach is made easier using its Cephaguard DC dry cow therapy.
While a 60 day drying off period is required for some cows, others may not need to be withdrawn from milk production for the full period, including those with a high body condition score in late lactation, high yielders and older healthy cows with an increased tendency for weight gain. For cows in these categories, a shorter drying off period can mean additional days of milk production and extra income for the farmer with no negative impact on future lactations or the cow's overall health.
The Yield Wheel shows how production and income can be maximised on a sliding scale from a standard 60 day drying off period down to 36 days, the shortest drying off period. It also shows the benefits which can be gained in terms of reduced discarded milk days in the case of cows with an unclear calving date.
Cephaguard DC dry cow therapy is the most recent entrant to the dry cow therapy market. With its 35+1 day withdrawal period in milk, Virbac says it offers farmers increased flexibility for the management of dry periods.
Brigitte Goasduf, Ruminants Product Manager at Virbac said: "For dairy farmers, it's all about milk. They're looking to optimise production and reduce waste while also ensuring that they treat infections effectively at drying off and prevent new infections which may reduce yield during the next lactation.
We've produced the Yield Wheel to highlight the tangible benefits of taking a customised and more flexible approach to drying off using Cephaguard DC. The data is provided in a practical and straightforward way and demonstrates the potential yield benefits that can be achieved from an overall herd management and income perspective. We hope it will prove a useful tool."
Pfizer has released the results of its first Performance Index (formerly the Fort Dodge Index) which shows mildly improved trading conditions for the companion animal veterinary market in the first quarter of 2011.
Those aspects of veterinary business that showed an improvement in the first quarter of 2011 include: turnover growth (+0.8%, up from -0.1% in March 2010); client retention (+0.1%); the average number of visits per year (+ 0.17%); annual transaction value (+ 1.1%); average transaction value (+0.8% to £41.74); fee per product service (+0.2%) and products and services sold per visit (+0.6%).
Leveraged sales (typically pet-care products), which were down 2% (from 40% to 38%) in 2010, have increased 0.9% in the first quarter of 2011 to make up 39% of practice transactions.
Less positively and pointing to the need for veterinary practices to implement ongoing marketing initiatives, the number of new clients coming into practice is down (-0.4%) as is the number of active clients (-0.26%). Revenue from loyal clients (those that visit the practice for additional products and services, particularly vaccination and other preventative healthcare programmes) was static. Although flat growth is an improvement on previous reports, this is still a concern, as it is these clients who are the driver for revenue growth in many practices.
Pfizer Business Consultant, Simon Fowler said: "Although the figures are only very slightly improved this does mirror what we are seeing in practices that we visit. Practice turnover growth of 0.8%, while only small, is much better than any quarter in 2010. So we may be seeing the first green shoots of recovery, but there's still no room for complacency. Before we all breathe a collective sigh of relief, however, it should be remembered that as this is the first report for 2011 it is only an early picture, while a fuller story will be gleaned from the second report, which will show results from the first six months of the year.
"What is clear is the need for practices to market themselves in order to attract new clients, increase growth from active clients and increase client loyalty. VetSupport+ includes a range of marketing services to help practices in this respect. A practice has already achieved TV coverage via our Public Relations support service, while others are using PressRoom newsletter templates to keep potential and existing clients up to speed with the practice's news."
Further information about Pfizer's VetSupport+ service is available at www.vetsupportplus.co.uk.
RCVS President Peter Jinman has announced that a review will be carried out into the circumstances that led to higher-than-expected expenditure on the College's new database and development works in the Lower Ground Floor at Belgravia House.
He said: "That the work was required was not in question, but that expenditure over the extended timescale of both projects rose above initial budgets is both to be regretted and subject to analysis as to cause."
The RCVS Officer team has asked Professor Bill McKelvey - a new member of the College's Governance Review Group - and two of the College's Privy Council-appointed Council members to look at all aspects that relate to its budgeting and expenditure process.
The setting up of the enquiry has been cleared and approved by Sir David Barnes, who chairs the RCVS Governance Review Group.
All reports from Professor McKelvey will be scrutinised by the Governance Review Group, Officers, the Planning and Resources Committee and Council.
Following a survey which indicates that veterinary surgeons are largely using unproven supplements to manage early-stage osteoarthritis, Hill's Pet Nutrition is calling upon vets to use evidence-based clinical nutrition to manage the condition.
The survey, which was carried out by independent market research firm Zyman Group, found that vets are more likely to give supplements than any other treatment in early stage osteoarthritis: 66% of cases receive supplements, 45% are given NSAIDs, and only 20% receive dietetic pet food.2
According to Hill's, its Prescription Diet j/d dry is clinically proven to improve mobility in osteoarthritic dogs in as little as 21 days; and 28 days in cats.3,4 Furthermore, the clinical study assigned to j/d is classified as Grade 1 level evidence - the highest grade reflecting the validity of clinical evidence. Another study has shown that Prescription Diet j/d also helps reduce NSAID dosage by up to 25 percent in dogs.5 This quality of evidence is, says Hill's, in contrast to many supplements.
John Innes, Professor of Small Animal Surgery at Liverpool, was involved in some of the early work on j/d: "Our results showed that the EPA in Hill's Prescription Diet j/d Canine pet food helped to reduce proteoglycan loss from cartilage. This would have beneficial effects in helping to preserve loss of cartilage. By preserving the cartilage, we can reduce pain in the long-term and ensure greater mobility for dogs with osteoarthritis."
Hill's has also announced that because a substantial majority of vets and nurses said that they felt that natural GACs have a positive effect in osteoarthritis1, its Prescription Diet j/d dry has been enriched with glucosamine and chondroitin sulphate.
Hill's j/d programme is now backed with money off vouchers, to improve client acceptance of veterinary recommendation. Clients who register on the website http://www.hillspetmobility.co.uk/,or http://www.hillspetmobility.ie/, will receive two £10 (or €10) money off e-coupons to use in clinic on their next purchases of j/d. They will also receive monthly e-mails containing information on how to take care of their pet with mobility problems, and help drive them back into the clinic for check-ups.
Veterinary surgeons who would like more information on the studies proving clinical efficacy, or score cards and trial guides for clients, should contact their Hill's Territory manager or call 0800 242438 or in ROI 1 800 626002. Clients can also fill in the scorecard online at www.hillspetmobility.co.uk or http://www.hillspetmobility.ie/
References
Pfizer has repeated it's call for veterinary practice staff to take part in its Vet Support+ independent, industry-wide survey of employee engagement.
The survey gives practice team members, who are not partners or owners, the chance to have their say about their role and career and the future of the profession. Participants are asked to consider how they feel towards their practice and delve into issues on teamwork and communication, management techniques, personal development opportunities and working environment.
More than 3,000 vet practice staff have already completed the survey, a phenomenal early response which suggests practice employees are keen to have their voices heard. However, the closing date for the survey isn't till Friday 29th July, so if you haven't yet had a chance to do the survey, there is still time.
Pfizer Business Consultant, Vanessa Wilson, has more than 20 years experience helping businesses, teams and individuals achieve their goals. She is not surprised at the significant early response: "Questions on the level of employee engagement and satisfaction come up all the time in the work we do with practices. I'm not surprised that staff are using this opportunity to have their voice heard.
"Once completed, this survey will provide some very useful data and direction for the industry as a whole and I'd like to think it will identify opportunities for both individual career development and practice growth."
All members of staff employed within a practice who have not received a mailing and wish to participate are welcome to respond online. http://www.noesis-mi.com/surveys/employeesurvey/.
Pfizer says the findings, which are expected to be released in the autumn, will deliver a national and regional view of the current employee engagement landscape.
For further information about Vet Support+ Business Services from Pfizer visit www.vetsupportplus.co.uk.
The European Commission has agreed with the BSAVA and BVA that controls must be maintained to keep the UK free from the tapeworm Echinococcus multilocularis, and adopted a regulation that will permit pre-movement treatment for dogs travelling to listed Member States (i.e. the UK, Ireland, Finland and Malta).
In June Defra announced that the UK's derogation from European pet travel rules, which allows additional protection for the UK against rabies, ticks and tapeworms, would end on 31 December 2011. The movement rules on rabies and ticks will now be harmonised with the rest of Europe.
However, due to the significant public health risk posed by Echinococcus multilocularis, the BVA and BSAVA (working with Defra, the Federation of Veterinarians of Europe [FVE] and colleagues in Veterinary Ireland) continued to lobby the European Commission for controls on tapeworms to be maintained.
The regulation will ensure that a dog must be treated by a veterinary surgeon 24 to 120 hours (1-5 days) before entering one of the listed countries.
The BVA and BSAVA say they made a scientific case for a treatment window of 24-48 hours, but accept that the Commission had to find a compromise that would assist pet owners travelling during national holidays.
Harvey Locke, President of the BVA said: "This has been a long process but the BVA and BSAVA put forward the strong scientific case for the UK to maintain tapeworm controls and we are delighted that the European Commission has adopted this resolution.
"In our role as guardians of public health, vets were deeply concerned that the removal of tapeworm controls would see the introduction of EM to the UK and Ireland.
"Although relatively benign in dogs, the resulting disease in humans - alveolar echinococcosis - is an invasive, cancer-like cystic stage of the parasite, and is invariably fatal if not treated.
"The next stage of our lobbying will be to ensure that Member States and MEPs from across Europe support the UK's case for the additional controls."
Andrew Ash, President of BSAVA said: "Echinococcus multilocularis is a significant public health threat and we have worked hard to ensure the European Commission understands the potential impact of allowing this zoonotic disease to enter our country.
"The BVA and BSAVA will continue to promote the best possible health and welfare advice for pet owners taking their animals abroad. Our advice to owners is to speak to a vet as early as possible to make sure pets are protected from all diseases and parasites encountered abroad."
Fabtek Solutions has announced the launch of Meditek, an activated carbon wound dressing which has been impregnated with silver to enhance its antibacterial qualities.
Joy Coutts from Fabtek Solutions said: "Meditek uses Zorflex which is a 100% pure activated carbon fibre. It has a huge surface area due to its microporous structure, and a permanent electrostatic charge that attracts bacteria towards it, where they are immobilised and retained. When removed from the substrate, the bacteria die, but the microscopic particulates of metallic silver accelerate the bacteria kill.
"Better still, Meditek carries no risk phases as it's non toxic and non invasive."
Joy added: "We are commercial members of the Vet Wound Library, an initiative designed to help promote modern wound care to veterinary professionals, it also means members can try our dressings for free."
According to Fabtek, Meditek has been tried and tested by vets and produced excellent results. The company's website also features some case studies which show the wound before and after the use of Meditek.
Dressings are available in 10cm x 10cm, and 15cm x 25cm sizes, which can be cut to fit. Prices start from £35 for a box of five.
For more information, see http://www.fabteksolutions.com/, email admin@fabteksolutions.com or call 07794094011.
The RCVS Charitable Trust has teamed up with the Foundation for Social Improvement (FSI) for the launch of the Great Big Small Charity Car Draw 2011.
The draw enables small charities, such as the RCVS Charitable Trust, to sell tickets to supporters which offer a chance of winning a brand new Fiat 500 1.2 Pop. Each ticket costs only £2, and the Trust will receive £1.90 for every ticket it sells.
Tickets can be bought securely online at http://trust.rcvs.org.uk/support-us/get-involved/win-a-fiat-500/ or directly from the Trust office on 020 7202 0721 or by emailing fundraising@rcvstrust.org.uk. Books of tickets are also available to sell to colleagues, friends and family. The deadline for buying tickets is September 16th 2011 with the draw taking place on 25th October 2011.
Here are a few examples of what reviewers have been saying about the Fiat 500:
"The Fiat 500 is both stylish and fun. The modest running costs complement the engaging handling. So, this nimble little city car can be enthusiastically thrown into corners and it should emerge grinning like a Cheshire Cat." Motoring.co.uk
"I love my Fiat 500 1.2 Pop from the moment I drove off in it. Great fun to drive on the motorway and in town for parking into slots others cannot!" What Car?
"It's absolutely fantastic. It drives like a dream. Everybody admires it." Fiat Forum
For further information on the car draw, please contact Fiona O'Regan on 020 7202 0743 or Rebecca Fellows on 020 7202 0721. Alternatively email fundraising@rcvstrust.org.uk.
Novartis Animal Health has announced that Crovect 1.25% Pour-On solution for sheep, a broad spectrum ectoparasiticide, is now licenced for the treatment of ticks, with a persistent efficacy of ten weeks and the majority killed within three hours.
Crovect also works in the treatment and control of headflies, the treatment of biting lice, and the prevention and treatment of blowfly strike in sheep.
Crovect has a meat withhold period of eight days. Novartis says this makes Crovect the long-lasting tick treatment with the shortest meat withhold period available, which is of use to farmers taking lambs to market at this time of year.
Helen Langham, Brand Manager at Novartis Animal Health said: "Farmers now have another option available for effective and long lasting tick treatment for their flocks, and one that can be flexibly used in lambs to be marketed. This should greatly reduce the worry of tick infestation along with the associated welfare and economic problems, and we are pleased to bring this solution to the market".
Unite, the largest trade union in the country, has announced that up to 17,000 members of the UK veterinary profession could become members within the next five years, following the establishment of the British Veterinary Union (BVU)The union says it will be able to give veterinary surgeons, veterinary nurses, practice managers, support staff and students in all disciplines, the additional muscle to tackle employment problems in the workplace, such as pay, contracts, bullying and professional development.Unite's General Secretary, Len McCluskey said: 'As a progressive trade union, Unite warmly welcomes BVU into the Unite family. The fact that a highly-regarded profession is looking to Unite for support in employment matters is an indication of the validity and relevance of trade unions in 2011 Britain.' Dr Shams Mir, Chairman, Professional Advisory Committee, British Veterinary Union in Unite said: 'Our biggest challenge will be to change the mindset of our profession to address the deep-trenched problems of working conditions and terms of employment for vets and nurses, and safeguarding their professional status. But, most importantly, we have to overcome the sense of fear amongst veterinary professionals in raising legitimate employment issues.''Veterinary professionals face the same problems in their working lives as any other health professionals, but never before have vets had a trade union to support and represent them. BVU in Unite is a great opportunity for the profession to develop and expand, and is a goal that many have aspired to for years. We believe that up to 17,000 veterinary professionals could join BVU in Unite in the next five years.'Dr Mir said that research has revealed that vets suffer from much higher levels of anxiety and depressive symptoms and they are five times more likely to have suicidal thoughts and four times more likely to commit suicide compared to the general UK population.
He said: 'Sadly, according to the most recent Royal College of Veterinary Surgeons' survey of the profession, nearly half of the responding vets and nurses said that if they had their time again, they would choose a different profession.' 'This is a wake-up call for our profession and we must act to address all the underlying problems leading to this situation.'
Further information is available at: www.bvu.org.uk and www.unitetheunion.org/bvu
Virbac has announced that it will repeat its EasOtic promotion through which practitioners that make multiple purchases of the award-winning otitis treatment can claim an ear model and specialist ear instrument kit.
The models, which show the anatomy of a healthy canal on one side and the changes associated with chronic damage on the other, are approximately 15cm high and can be used as a visual aid to show clients the consequences of untreated chronic ear disease.
The specialist ear instrument kits, worth £100, have been designed in consultation with veterinary dermatologists. They consist of a haemostat, ear forceps, three various cerumen scoops and a Spreulls ear-flushing needle.
Product Manager Chris Geddes MRCVS said: "Basically it's the best ear equipment for daily use by practitioners. Last year we were overwhelmed by the demand of both promotions, so we've decided to repeat the offer again this year."
The models and kits are available with multiple purchases of EasOtic and the neutral pH glycotechnology ear cleaner Epi-Otic.
For details of how you can obtain a model and/or kit for your practice contact your local Virbac territory manager or call Virbac on 01359 243243.
The British Veterinary Association and its specialist cattle division the British Cattle Veterinary Association have welcomed today's announcement by Defra that it is strongly minded to include a controlled cull of badgers as a key component of the bovine tuberculosis (TB) eradication plans for England.
The two associations have long supported the need to control TB in both cattle and wildlife, including the need for a targeted, humane cull of badgers in specific parts of the country.
Following a consultation exercise which closed in December 2010, Defra has today announced:
The BVA and BCVA jointly responded to Defra's 2010 consultation to say that the available science supported the case for a badger cull, alongside the need for stricter cattle control measures, in those areas where badgers are regarded as a significant contributor to the persistent presence of TB. The response also emphasised strongly that any cull of badgers had to be done in a humane and effective manner.
The BVA and BCVA say that today's announcement shows Defra has listened closely to their concerns. Through the consultation response the BVA and BCVA raised the issue of the efficacy of an industry-led cull using controlled shooting (as opposed to cage trapping and shooting) and stated firmly that any cull must be monitored for humaneness. Both of these issues have been considered in depth by Defra and appear to have been addressed in the plans.
The associations say they will be looking closely at the detail of the guidance issued today and will be responding to the consultation.
Harvey Locke, President of the BVA, said: "The BVA and BCVA have long argued for a targeted, humane badger cull to be used alongside stricter cattle controls. We believe that failure to tackle wildlife sources of TB infection has prolonged the presence and enhanced the spread of infection in all affected species populations.
"We recognise that this is a very emotive and difficult decision but we believe that the science supports this policy and we support Defra's commitment to tackling this devastating disease.
"We are particularly pleased that this announcement has not been delayed until after the summer recess, which demonstrates the seriousness of the need to tackle TB."
John Fishwick, President of BCVA, added: "We welcome today's announcement which indicates that a humane and carefully targeted cull of badgers can contribute to the control of this dreadful disease.
"We are particularly pleased that the veterinary profession's concerns that any cull must be humane and well monitored appear to have been listened to and we will now study the proposals in detail.
"An industry-led cull will be an enormous undertaking for everyone involved and it is vital that we get the detail right from the outset; for the sake of cattle, wildlife and industry."
Meanwhile, the RSPCA has expressed its devastation at the announcement.
According to the charity, new research has been published which shows that badger culling can more than double the risk of TB infecting cattle1. High-profile voices such as Sir David Attenborough and government adviser Lord John Krebs have also weighed in, saying a cull could "make the situation worse" and be "ineffective".
David Bowles, Director of Communications for the RSPCA, said: "Today is a black day for badgers - a day we have been dreading.
"At a time when the Welsh government has stepped back from a cull, the government in England is slowly shredding its own animal welfare credentials."
The RSPCA says it agrees that action is needed to combat bovine TB in cattle, but does not think action is synonymous with culling. The charity believes that vaccination of badgers, increased levels of testing, improved biosecurity and stricter controls on the movement of cattle are more effective ways of dealing with the problem in the long-term and eradicating bovine TB in cattle for good.
Colin Booty, senior scientist for the RSPCA, said: "The RSPCA is sympathetic to farmers struggling to cope with the effects of this crippling disease and thinks that the problem of bovine TB in cattle needs a sustainable and effective solution.
"But this is not such a solution. We believe that the government have taken the wrong fork in the road with this risky policy.
"This cull will contribute little or nothing to the long-term goal of eradicating TB nationally. Instead it will wipe out huge numbers of this much-loved species, including many animals which are healthy."
1 The New Medical Research Council study came from Imperial College London and were published in the Royal Society Journal Biology Letters. They were based on analysis of data from the 10-year Randomised Badger Culling Trial set up by the Department for Environment, Food and Rural Affairs (Defra) in 1998.
The Animal Health Trust has cut the first sod of a new cancer centre for animals in Suffolk.
The AHT's Cancer Centre will provide all three treatment options: surgery, chemotherapy and radiotherapy, on one site. The cancer facility is being purpose-built to treat horses, dogs and cats.
Sue Murphy, Head of Clinical Cancer Treatment at the AHT, said: "Having all three treatment options on one site means that whatever the diagnosis, we will be able to offer each and every patient the very best options for their specific case. With one in four dogs and one in six cats developing cancer at some time in their life this new centre will help many more animals - from Suffolk, East Anglia and all across the UK."
The new centre will also further research into cancer. Treating animals with all types of the disease will enable the AHT's vets and scientists to expand current knowledge about cancer. This will help with the development of new ways to diagnose and treat the disease.
Vets and scientists at the AHT already work collaboratively with cancer researchers looking at the disease in humans. There are a number of links between human and animal cancers which have already been identified. It is hoped that knowledge gained from the AHT Cancer Centre may also help in the understanding of cancer in people.
The AHT hopes the building will open in summer 2012 . It is launching an appeal to raise much needed funds to equip the centre with a linear accelerator. This piece of specialist equipment works by delivering high-energy radiation beams to break cancerous tumours down while sparing the surrounding normal tissue.
The AHT Cancer Centre will be one of only six veterinary facilities in the UK to house a linear accelerator.
Sue Murphy added: "Currently, there is no way to tell which animals will, and which animals won't, develop cancer. It could happen to any animal at any time. This new centre will give more animals a fighting chance of beating the disease, enabling them to lead long and healthy lives. The fact that treatments developed to benefit our pets may also lead to improvements in the prevention and treatment of cancer in humans makes this centre all the more important.
"I would urge you to donate whatever you can to help equip the centre. Your donation, however large or small, will help many more animals beat cancer and it may also help in the fight against cancer in people."
If you would like to make a donation to the AHT Cancer Centre please visit www.aht.org.uk or telephone 01638 555648.
Alternatively you can make a £5 donation by textingVETS24 £5 to 70070
Ceva Animal Health has highlighted a new meta-analysis1 which, according to the company, reveals that there is a significant (P< 0.001) association between the use of pharmacotherapy (fluoxetine and clomipramine) or pheromonatherapy (Feliway) and reduction or elimination of feline urine marking.
Ceva says this is the first time a meta-analysis technique has been used to evaluate the efficacy of interventions in veterinary behavioural medicine; the study assessed all published papers covering treatments for feline urine spraying. Ten studies in nine publications were analysed, despite their different study designs. In order to carry out the meta-analysis, the papers were rated according to importance and a 'placebo-effect' was calculated. Primary and secondary outcomes were also identified, with the primary outcome being the 'number of cats that either ceased or reduced spraying by at least 90%' and the secondary outcome being 'the number of cats that reduce spraying from baseline levels'.
Information is available by calling Lucy Brett at CEVA Animal Health on 01494 781510.
1. A meta-analysis of studies of treatments for feline urine spraying. Daniel S Mills, Sarah E Redgate, Gary M Landsberg. PLos ONE, April 2011, Volume 6, Issue 4
The RCVS Disciplinary Committee has suspended a Cardigan veterinary surgeon from the RCVS Register for five months, for failure to perform accurate bovine tuberculin testing and for falsely certifying the test results.
During the two-day hearing, Dewi Wyn Lewis, of Priory Veterinary Ltd, Cardigan, answered charges about inaccurate skin fold measurements and false certification relating to two visits he made as an Official Veterinarian to a farm in April 2009 to undertake tuberculin testing.
Mr Lewis accepted that he had not carried out the tuberculin tests in the way required by Animal Health (AH) - an Executive Agency of the Department for Environment, Food and Rural Affairs - and had taken short cuts to save time. However, he denied the charges, arguing that, although instructions to Official Veterinarians clearly required the use of callipers to measure the skin folds of cattle necks on Day One of testing, not using callipers and using his finger and thumb did not amount to failing to measure.
He also argued (and it was accepted by the Committee) that, regarding Day Two of testing, there was inconsistency in AH's instructions on calliper use, which in written form required using callipers for measuring every animal but in practice accepted use of callipers when a reaction could be detected by manually palpating the skin. On Day Two, Mr Lewis said, he had done what AH required: he had used callipers on the cattle he identified for closer examination.
The Committee, however, found that by failing to use callipers on the first day, as required by AH, Mr Lewis had failed to measure the skin folds of almost all of the 104 cattle. The Committee was also satisfied that, on the second day, 10-20% of the herd were not even touched by Mr Lewis and the Committee accepted the evidence of the three other witnesses present during the testing, which indicated that Mr Lewis had failed to carry out careful assessment and manual palpation of every animal.
The Committee then considered whether Mr Lewis had dishonestly signed the certificate, or had signed a false certificate which he ought to have known was inaccurate. The Committee noted that there were no previous Disciplinary findings against Mr Lewis, and was prepared to believe his assertion that, although he knew he had not carried out the tests in strict compliance with AH's instructions, he genuinely believed his methods to be at least as accurate as measuring with callipers and did not think he was doing anything wrong or dishonest. The Committee could not then be sure that Mr Lewis had realised what he was doing was dishonest. However, the Committee noted that 'false' also means 'inaccurate' and, as Mr Lewis ought to have known that as his testing methods were not adequate, he also should have known that a considerable number of measurements on the certificate were inaccurate and that the certificate itself was inaccurate.
After considering the facts of the case, the Committee concluded that Mr Lewis's actions amounted to serious professional misconduct and directed that he should be suspended from the Register for five months, after which he may return to practice. In relation to the sanction, the Committee said: "In reaching this decision it is relevant that the false certification was not dishonest and that there was professional and personal mitigation put forward on behalf of Mr Lewis. The Committee has paid regard to the fact that Mr Lewis is an experienced veterinary surgeon who is highly thought of in his local area. It does not believe that there is any likelihood that he will repeat his previous conduct."
The Committee also said it gave considerable weight to the fact that Mr Lewis had had to wait an additional three-month period for the hearing because of an earlier adjournment.